GLP-1 receptor agonists play a key role in weight management
This small structural change had a massive impact on its function
Pathogen-induced tissue-resident memory T H 17 (T RM 17) cells amplify autoimmune kidney disease
Previously, he worked as a Research Scientist at the Federal University of Rio de Janeiro and was a Graduate Student Researcher at Gustave Roussy
Lilly claims retatrutide delivers bariatric-level weight loss in trial Lilly claims retatrutide delivers bariatric-level weight loss in trial In Business news Follow this topic Bookmark Record learning outcomes Mounjaro manufacturer Lilly has said retatrutide, a triple hormone receptor agonist product currently in development, helped patients achieve powerful weight loss in a Phase 3 clinical trial
Other companies are working on their own weight-loss pills: Eli Lilly, which makes Zepbound, is developing a GLP-1 pill, orforglipron, for weight loss and type 2 diabetes, with FDA approval anticipated for March 2026